Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Stein

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|April 16, 2025
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case reportTyler Ruemmele, Rodney Macedo, Mark N Stein, et al.
Frontiers in Oncology|June 17, 2017
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary ApproachBrian M Shinder, Kevin Rhee, Douglas Farrell, et al.
The Oncologist|April 4, 2022
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 StudyMark N Stein, Lawrence Fong, Ronald Tutrone, et al.
The American Journal of Medicine|March 15, 2011
Patterns and correlates of prostate cancer treatment in older menCalpurnyia B Roberts, Peter C Albertsen, Yu-Hsuan Shao, et al.
Journal of the National Cancer Institute|August 29, 2009
Contemporary risk profile of prostate cancer in the United StatesYu-Hsuan Shao, Kitaw Demissie, Weichung Shih, et al.
Archives of Internal Medicine|July 28, 2010
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/mlYu-Hsuan Shao, Peter C Albertsen, Calpurnyia B Roberts, et al.
Investigational New Drugs|August 11, 2010
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumorsBiren Saraiya, Rashmi Chugh, Vassiliki Karantza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsementStephen J Freedland, R Bryan Rumble, Antonio Finelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumorsYaqoob Ali, Yong Lin, Mecide M Gharibo, et al.
Clinical Genitourinary Cancer|October 19, 2015
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate CancerMark N Stein, Maha Hussain, Walter M Stadler, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|April 16, 2025
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case reportTyler Ruemmele, Rodney Macedo, Mark N Stein, et al.
Frontiers in Oncology|June 17, 2017
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary ApproachBrian M Shinder, Kevin Rhee, Douglas Farrell, et al.
The Oncologist|April 4, 2022
ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 StudyMark N Stein, Lawrence Fong, Ronald Tutrone, et al.
The American Journal of Medicine|March 15, 2011
Patterns and correlates of prostate cancer treatment in older menCalpurnyia B Roberts, Peter C Albertsen, Yu-Hsuan Shao, et al.
Journal of the National Cancer Institute|August 29, 2009
Contemporary risk profile of prostate cancer in the United StatesYu-Hsuan Shao, Kitaw Demissie, Weichung Shih, et al.
Archives of Internal Medicine|July 28, 2010
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/mlYu-Hsuan Shao, Peter C Albertsen, Calpurnyia B Roberts, et al.
Investigational New Drugs|August 11, 2010
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumorsBiren Saraiya, Rashmi Chugh, Vassiliki Karantza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsementStephen J Freedland, R Bryan Rumble, Antonio Finelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumorsYaqoob Ali, Yong Lin, Mecide M Gharibo, et al.
Clinical Genitourinary Cancer|October 19, 2015
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate CancerMark N Stein, Maha Hussain, Walter M Stadler, et al.
Pageof 10